XML 54 R48.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Revenue Recognition - Contract Balances - Additional Information (Details) | 1 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | ---
Oct. 31, 2023 USD ($) | Aug. 31, 2022 USD ($) | Jun. 30, 2024 USD ($) Obligation | Dec. 31, 2023 USD ($) | Aug. 31, 2023 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |
Accounts receivable |  |  | $ 0 | $ 0 |
Contract liabilities |  |  | $ 0 | $ 0 |
Reimbursement period of costs incurred for quarter ended |  |  | 75 days |  |
GSK |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |
Reimbursement period of costs incurred for quarter ended |  |  | 75 days |  |
GSK Collaboration Agreement |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |
Number of performance obligations | Obligation |  |  | 6 |  |
Pol Theta Program |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |
Additional milestone payment potentially received clinical evaluation |  |  | $ 10,000,000 |  |
Milestone payment received for achievement of earlier preclinical development milestone |  | $ 3,000,000 |  |  |
Milestone payment received clinical evaluation |  |  |  |  | $ 7,000,000
Reimbursement period of costs incurred for quarter ended |  |  | 90 days |  |
WRN Program |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |
Milestone payment received for achievement of earlier preclinical development milestone | $ 3,000,000 |  |  |  |
Milestone payment received clinical evaluation | $ 3,000,000 |  |  |  |
Reimbursement period of costs incurred for quarter ended |  |  | 75 days |  |
Determination period of costs incurred |  |  | 75 days |  |

X
- Definition Additional milestone payment potentially received clinical evaluation + References No definition available. + Details
Name: | idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The period to determine an amount of reimbursable costs. + References No definition available. + Details
Name: | idya_DeterminationPeriodOfCostsIncurred
Namespace Prefix: | idya_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment received clinical evaluation + References No definition available. + Details
Name: | idya_MilestonePaymentReceivedClinicalEvaluation
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payment received for achievement of initial preclinical development milestone. + References No definition available. + Details
Name: | idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of performance obligations. + References No definition available. + Details
Name: | idya_NumberOfPerformanceObligations
Namespace Prefix: | idya_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement period of costs incurred. + References No definition available. + Details
Name: | idya_ReimbursementPeriodOfCostsIncurred
Namespace Prefix: | idya_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |